Literature DB >> 15141714

Atrial septal defect with borderline pulmonary vascular disease: surgery and long-term oral prostacyclin therapy for recalcitrant pulmonary hypertension.

Hitoshi Yamauchi1, Shigeo Yamaki, Masahiro Fujii, Yoshiaki Saji, Masami Ochi, Kazuo Shimizu.   

Abstract

The hemodynamic determination of operability in atrial septal defect (ASD) with severe pulmonary hypertension is problematic. Therefore, we perform an open lung biopsy prior to the corrective surgery in cases with pulmonary vascular resistance greater than 8 units x m2 and/or pulmonary arterial peak pressure greater than 70 mmHg. We present 4 cases showing occlusion of more than 70% of the small pulmonary arteries and arterioles by musculoelastosis, thromboembolism and mixed-type (musculoelastosis and plexogenic arteriopathy) which was considered borderline in terms of operability. After complete closure of the ASD and postoperative long-term oral prostacyclin (PGI2) therapy, pulmonary artery peak pressure decreased from 110-72 (mean 84) to 105-45 (mean 74) mmHg immediately after operation and 65-40 (mean 57) mmHg after PGI2 therapy. The New York Heart Association functional status of the patients improved from class II-III to class I with oral PGI2 only. Our cases demonstrate that despite more than 70% occlusion of the small pulmonary arteries and arterioles, surgery and long-term PGI2 therapy can reduce pulmonary artery pressure and improve the quality of life.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15141714     DOI: 10.1007/s11748-004-0112-1

Source DB:  PubMed          Journal:  Jpn J Thorac Cardiovasc Surg        ISSN: 1344-4964


  8 in total

1.  Reduction in recalcitrant pulmonary hypertension after operation for atrial septal defect.

Authors:  H Yamauchi; S Yamaki; M Fujii; H Iwaki; S Tanaka
Journal:  Ann Thorac Surg       Date:  2001-09       Impact factor: 4.330

2.  Oral beraprost sodium improves exercise capacity and ventilatory efficiency in patients with primary or thromboembolic pulmonary hypertension.

Authors:  N Nagaya; Y Shimizu; T Satoh; H Oya; M Uematsu; S Kyotani; F Sakamaki; N Sato; N Nakanishi; K Miyatake
Journal:  Heart       Date:  2002-04       Impact factor: 5.994

3.  Indications for surgery based on lung biopsy in cases of ventricular septal defect and/or patent ductus arteriosus with severe pulmonary hypertension.

Authors:  S Yamaki; H Mohri; K Haneda; M Endo; H Akimoto
Journal:  Chest       Date:  1989-07       Impact factor: 9.410

4.  Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects.

Authors:  E B Rosenzweig; D Kerstein; R J Barst
Journal:  Circulation       Date:  1999-04-13       Impact factor: 29.690

5.  Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension.

Authors:  T Saji; Y Ozawa; T Ishikita; H Matsuura; N Matsuo
Journal:  Am J Cardiol       Date:  1996-07-15       Impact factor: 2.778

6.  An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension.

Authors:  B W Christman; C D McPherson; J H Newman; G A King; G R Bernard; B M Groves; J E Loyd
Journal:  N Engl J Med       Date:  1992-07-09       Impact factor: 91.245

7.  Secundum atrial septal defect with severe pulmonary hypertension. Open lung biopsy diagnosis of operative indication.

Authors:  S Yamaki; T Horiuchi; M Miura; K Haneda; E Ishizawa; Y Suzuki
Journal:  Chest       Date:  1987-01       Impact factor: 9.410

8.  Longitudinal smooth muscle in pulmonary arteries. Occurrence in congenital heart disease.

Authors:  C A Wagenvoort; J Keutel; W J Mooi; N Wagenvoort
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1984
  8 in total
  1 in total

Review 1.  Pulmonary hypertension complicating congenital heart disease.

Authors:  J Eduardo Rame
Journal:  Curr Cardiol Rep       Date:  2009-07       Impact factor: 2.931

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.